Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News COMPASS Pathways Plc CMPS

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known... see more

Opinion & Analysis (NDAQ:CMPS)

No current opinion is available.

Bullboard Posts (NDAQ:CMPS)

Sell buddy sell.

Otherwise you guys out there will be losing your shorts with this stock today and
coolfooldumbguy - June 23, 2025

COMPASS Pathways plc: Advancing Psilocybin Therapy with Prom

http://beyondspx.com/2024/07/31/compass-pathways-plc-advancing-psilocybin-therapy-with-promising-ptsd-data-and-pivotal-trd-trials-on...
MikeTester - August 2, 2024

Buy for me here, stock seems cheap.

Stage 3 trials
FukDaFed - February 22, 2022

The declining sp is affecting my mental health

This stock is not getting very much love. 
MushLove - December 12, 2021

Compass Pathways Granted Its Tenth Overall Patent Related To

Compass Pathways this morning issued a brief release, indicating it has been granted a fifth patent in the United States. The patent is...
AwareInvestor - November 23, 2021

Compass Pathways Closes Enrollment For Phase IIb Psilocybin

Compass Pathways this morning provided a brief update to the market on the latest status of its ongoing phase IIb psilocybin therapy...
AwareInvestor - June 28, 2021

Podcasts